Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources
Authors: Steven Kurtzman, M.D
- Home
- About
- Brachytherapy
Patient Information
Clinician Information
Cesium 131 Products
- Theranostics
- Newsroom
- Investor Center
- Contact us
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
Authors
Amar U. Kishan, MD; Ryan R. Cook, MSPH; Jay P. Ciezki, MD; et al
- Published in journal:
JAMA
March 6, 2018
Related posts
Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.
Authors: Moran BJ, Rice SR, Chhabra AM, Amin N, Braccioforte M, Agarwal M.
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris, MD, FRCPC, W. James Morris MD, FRCPC, Scott Tyldesley, MD, FRCPC, …
The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Authors: Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V.
Company
Brachytherapy
Theranostics
Company
©2023. All rights reserved. Terms & Privacy | Privacy Policy